Equity Overview
Price & Market Data
Price: $15.82
Daily Change: +$0.03 / 0.19%
Range: $15.25 - $15.88
Market Cap: $424,252,832
Volume: 100,844
Performance Metrics
1 Week: 10.32%
1 Month: 18.24%
3 Months: -5.10%
6 Months: 88.78%
1 Year: 382.3%
YTD: 18.77%
Company Details
Employees: 31
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, and commercializing pharmaceutical products for rare diseases. The company offers INCRELEX, treatment for children who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD); ALKINDI SPRINKLE, as a replacement therapy for Adrenocortical Insufficiency (AI) in children under 17 years of age, and accurate dosing for newborns and children with AI; GALZIN, as a maintenance treatment for patients with Wilson Disease who have been initially treated with a chelating agent; PKU GOLIKE, medical formula for the dietary management of phenylketonuria (PKU); Carglumic Acid, treatment of acute and chronic hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency; Betaine Anhydrous, for the treatment of homocystinuria; Nitisinone for the treatment of tyrosinemia type 1; and Amglidia for the treatment of neonatal diabetes mellitus products. It also develops ET-600 for the treatment of central diabetes insipidus; ET-700 for the treatment of treatment of Wilson disease; ET-800; Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.